Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Nephrology

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Glomerulonephritis Clinical Trials

A listing of Glomerulonephritis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (8) clinical trials

Primary Objective: To assess the efficacy of Orelvo (voclosporin) compared with placebo in achieving renal response after 52 weeks of therapy in subjects with active lupus nephritis (LN) Secondary Objective: To assess the safety and tolerability of Orelvo over 52 weeks compared with placebo in subjects with active LN

Phase

Treatment of IgA Nephropathy According to Renal Lesions

Currently, IgAN treatment recommendations are only based on clinico-biological parameters. Steroids therapy appears to have a major role in IgAN treatment, but previous studies evaluating steroids lacked of optimal control group and reproducible evaluation criteria. No prospective study with optimal RAS blockade had included renal pathology in patients selection criteria, ...

Phase

Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy

Idiopathic Membranous nephropathy (IMN) is an immune-mediated glomerular disease characterized by deposition of IgG4 antibodies in the subepithelial area of the glomerular basement membrane (GBM). Proteinuria is the hallmark of the disease. The commonest presentation of IMN is nephrotic syndrome with preserved kidney function. The natural course of the disease ...

Phase

Sequential Therapy With Tacrolimus and Rituximab in Primary Membranous Nephropathy

PRIMARY AND SECONDARY ENDPOINTS/OUTCOME MEASURES Primary end-point: The proportion of patients reaching CR defined as a reduction of proteinuria since baseline level to a value equal or lower than 0.5 g/24 h proteinuria plus stable renal function (eGFR 45 ml/min/1.73m2) or PR defined as a reduction of proteinuria since baseline ...

Phase

Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation

This is a prospective study enrolling renal transplant recipients with the primary native kidney disease of FSGS. Primary endpoint is rate of recurrence of FSGS as seen in renal transplant biopsies and in rate of proteinuria. Secondary endpoint is renal function after transplantation The target subject number is 20 patients ...

Phase

Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy

Idiopathic membranous nephropathy is most common cause of glomerulonephritis in adults. Persistent high grade proteinuria or progressively decrease of renal function is a risk factor for end stage renal disease in idiopathic membranous nephropathy. It has been reported that cyclosporin in patients with idiopathic membranous nephropathy decreases proteinuria and improve ...

Phase

Aurinia Renal Response in Active Lupus With Voclosporin

The aim of the current study is to investigate whether voclosporin, added to the standard of care treatment in active lupus nephritis (LN), is able to reduce disease activity over a treatment period of 52 weeks. The background therapy will be MMF and initial treatment with IV methylprednisolone, followed by ...

Phase

Study of Sparsentan in FSGS

This is a randomized, multicenter, double-blind, parallel, active-control study. Approximately 300 patients aged 8 to 75 years (inclusive) will be enrolled in the study. The study will be conducted in approximately 150 study centers, globally. The investigational drug (sparsentan) is a dual acting angiotensin receptor blocker and endothelin receptor agonist. ...

Phase